S&P 500   4,550.52 (+0.00%)
DOW   35,399.98 (+0.19%)
QQQ   389.12 (-0.01%)
AAPL   190.01 (+0.12%)
MSFT   381.01 (+0.63%)
META   335.62 (+0.27%)
GOOGL   136.54 (+0.10%)
AMZN   146.83 (-0.61%)
TSLA   245.16 (+3.85%)
NVDA   477.20 (-1.08%)
NIO   7.20 (+0.14%)
BABA   76.28 (-1.61%)
AMD   121.70 (-0.77%)
T   16.18 (-0.19%)
F   10.34 (+0.00%)
MU   75.24 (-2.93%)
CGC   0.53 (-3.34%)
GE   119.14 (-0.69%)
DIS   93.87 (-1.37%)
AMC   6.66 (-2.06%)
PFE   29.71 (-1.43%)
PYPL   58.31 (+3.40%)
XOM   104.40 (+0.42%)
S&P 500   4,550.52 (+0.00%)
DOW   35,399.98 (+0.19%)
QQQ   389.12 (-0.01%)
AAPL   190.01 (+0.12%)
MSFT   381.01 (+0.63%)
META   335.62 (+0.27%)
GOOGL   136.54 (+0.10%)
AMZN   146.83 (-0.61%)
TSLA   245.16 (+3.85%)
NVDA   477.20 (-1.08%)
NIO   7.20 (+0.14%)
BABA   76.28 (-1.61%)
AMD   121.70 (-0.77%)
T   16.18 (-0.19%)
F   10.34 (+0.00%)
MU   75.24 (-2.93%)
CGC   0.53 (-3.34%)
GE   119.14 (-0.69%)
DIS   93.87 (-1.37%)
AMC   6.66 (-2.06%)
PFE   29.71 (-1.43%)
PYPL   58.31 (+3.40%)
XOM   104.40 (+0.42%)
S&P 500   4,550.52 (+0.00%)
DOW   35,399.98 (+0.19%)
QQQ   389.12 (-0.01%)
AAPL   190.01 (+0.12%)
MSFT   381.01 (+0.63%)
META   335.62 (+0.27%)
GOOGL   136.54 (+0.10%)
AMZN   146.83 (-0.61%)
TSLA   245.16 (+3.85%)
NVDA   477.20 (-1.08%)
NIO   7.20 (+0.14%)
BABA   76.28 (-1.61%)
AMD   121.70 (-0.77%)
T   16.18 (-0.19%)
F   10.34 (+0.00%)
MU   75.24 (-2.93%)
CGC   0.53 (-3.34%)
GE   119.14 (-0.69%)
DIS   93.87 (-1.37%)
AMC   6.66 (-2.06%)
PFE   29.71 (-1.43%)
PYPL   58.31 (+3.40%)
XOM   104.40 (+0.42%)
S&P 500   4,550.52 (+0.00%)
DOW   35,399.98 (+0.19%)
QQQ   389.12 (-0.01%)
AAPL   190.01 (+0.12%)
MSFT   381.01 (+0.63%)
META   335.62 (+0.27%)
GOOGL   136.54 (+0.10%)
AMZN   146.83 (-0.61%)
TSLA   245.16 (+3.85%)
NVDA   477.20 (-1.08%)
NIO   7.20 (+0.14%)
BABA   76.28 (-1.61%)
AMD   121.70 (-0.77%)
T   16.18 (-0.19%)
F   10.34 (+0.00%)
MU   75.24 (-2.93%)
CGC   0.53 (-3.34%)
GE   119.14 (-0.69%)
DIS   93.87 (-1.37%)
AMC   6.66 (-2.06%)
PFE   29.71 (-1.43%)
PYPL   58.31 (+3.40%)
XOM   104.40 (+0.42%)

Merck KGaA Stock Price, News & Analysis (ETR:MRK)

€159.85
-0.90 (-0.56%)
(As of 11/27/2023 ET)
Compare
Today's Range
€159.60
€161.95
50-Day Range
€137.85
€163.30
52-Week Range
€135.00
€202.80
Volume
234,553 shs
Average Volume
N/A
Market Capitalization
$20.66 billion
P/E Ratio
24.04
Dividend Yield
1.38%
Price Target
N/A

MRK stock logo

About Merck KGaA Stock (ETR:MRK)

Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

MRK Stock Price History

MRK Stock News Headlines

Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Merck to dish out up to $610M for Cambridge startup
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Merck: A Dividend Growth Stock Worth Considering
Merck’s Keytruda combo wins FDA approval for gastric cancer
At $100 Does Merck Stock Have Room For Growth?
Looking Into Merck & Co's Recent Short Interest
Merck Reports Higher Profit For Q3; Revises Full-year Outlook
See More Headlines
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
63,297
Year Founded
N/A

Profitability

Net Income
$2.89 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.43 billion
Cash Flow
€3.98 per share
Book Value
€64.92 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.66 billion
Optionable
Not Optionable
Beta
0.67
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Belen Garijo Lopez M.D. (Age 63)
    Chair of Executive Board & CEO
    Comp: $5.9M
  • Ms. Helene von Roeder (Age 53)
    CFO & Member of Executive Board
    Comp: $80k
  • Dr. Kai Beckmann (Age 58)
    CEO of Electronics & Member of the Executive Board
    Comp: $4.51M
  • Mr. Peter Guenter (Age 61)
    CEO of Healthcare Business & Member of Executive Board
    Comp: $5.2M
  • Dr. Matthias J. Heinzel (Age 56)
    CEO of Life Science Sector & Member of Executive Board
    Comp: $4.06M
  • Mr. Constantin Fest (Age 46)
    Head of Investor Relations
  • Dr. Friederike Rotsch (Age 51)
    Group General Counsel and Head of Group Legal & Compliance
  • Ms. Barbara Weiland (Age 49)
    Chief Compliance Officer
  • Mr. Dietmar Eidens (Age 65)
    Head of the Global HR Business Partner Organization
  • Mr. Frank Gotthardt
    Head of Corporate & Government Relations - Europe














MRK Stock Analysis - Frequently Asked Questions

How have MRK shares performed in 2023?

Merck KGaA's stock was trading at €180.90 at the start of the year. Since then, MRK stock has decreased by 11.6% and is now trading at €159.85.
View the best growth stocks for 2023 here
.

Is Merck KGaA a good dividend stock?

Merck KGaA (ETR:MRK) pays an annual dividend of €2.20 per share and currently has a dividend yield of 1.40%. The dividend payout ratio is 33.08%. This payout ratio is at a healthy, sustainable level, below 75%.

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include AbbVie (ABBV), Chevron (CVX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Eli Lilly and Company (LLY), Medtronic (MDT), AT&T (T), Adobe (ADBE), Aldeyra Therapeutics (ALDX) and Amgen (AMGN).

This page (ETR:MRK) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -